Omega-3 (Fish Oil)

Omega-3 fish oil is a source of the long-chain polyunsaturated fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), derived from fatty fish such as anchovies, sardines, mackerel, and salmon. These fatty acids are structural components of cell membranes throughout the body and are particularly concentrated in the brain and retina. Because the human body cannot synthesise EPA and DHA in meaningful amounts, they must be obtained through diet or supplementation.

Brands use omega-3 fish oil in gummy and sachet formats to address consumer demand for heart health, brain function, and eye health support. The ingredient has strong consumer recognition and a well-established regulatory framework in both the EU and US markets. For private-label manufacturers, omega-3 offers a mature category with clear positioning opportunities, though formulation challenges around taste and stability require careful attention.

Origin and history

The health benefits of fish consumption have been recognised for centuries, but the scientific identification of omega-3 fatty acids as the active component dates to the 1970s. Danish researchers Bang and Dyerberg observed low rates of cardiovascular disease among Greenland Inuit despite a high-fat diet rich in marine mammals and fish, sparking decades of research into EPA and DHA. By the 1990s, omega-3 supplements had entered the mainstream market, initially as softgels and later expanding into gummies, liquids, and functional foods.

Industrial production of omega-3 fish oil involves rendering fatty fish, refining the oil to remove contaminants, and concentrating EPA and DHA through molecular distillation or other techniques. The oil is typically stabilised with antioxidants such as vitamin E or rosemary extract to prevent oxidation. For gummy manufacturing, microencapsulated fish oil powders are often used to improve handling, stability, and taste masking compared to liquid oil.

Scientific overview

EPA and DHA are incorporated into cell membrane phospholipids, where they influence membrane fluidity, receptor function, and cell signalling. DHA is a major structural component of the brain and retina, while EPA serves as a precursor to signalling molecules called eicosanoids that modulate vascular function and platelet aggregation. The EFSA has reviewed extensive evidence and authorised claims for DHA's role in normal brain function, vision, and heart function, as well as EPA and DHA's combined role in maintaining normal blood pressure and triglyceride levels.

Bioavailability of omega-3 depends on the chemical form. Triglyceride-form fish oil has higher bioavailability than ethyl esters, and re-esterified triglycerides offer the highest absorption. In gummy formats, the oil is typically emulsified or microencapsulated to improve dispersion and stability. The manufacturing process must control for oxidation, as omega-3 fatty acids are highly unsaturated and prone to rancidity, which affects both taste and product quality.

Manufacturing watchpoints include temperature sensitivity during gummy production, the need for antioxidant protection, and the challenge of masking the characteristic fishy taste and odour. Microencapsulated powders with flavour-masking technology are the preferred form for gummy applications, though they add cost. The cost-per-mg of EPA+DHA is higher in gummy formats than in softgels due to the additional processing and lower payload per unit.

Omega-3 fish oil is one of the most familiar and commercially understood gummy actives across EU and US markets. Consumer awareness of omega-3 benefits for heart, brain, and eye health is high, making it a relatively easy ingredient to position. The category spans general wellness, prenatal nutrition, healthy ageing, and paediatric supplements, offering multiple positioning angles for brand differentiation. In the EU, the EFSA-authorised claims provide a clear regulatory pathway for on-pack communication.

Formulation and manufacturing tradeoffs are significant. Omega-3 fish oil is heat-sensitive, prone to oxidation, and has a strong taste that requires masking. Gummy production must use lower temperatures and incorporate antioxidants to preserve oil quality. Microencapsulated powders improve stability but reduce the EPA+DHA payload per gummy, meaning larger gummies or higher serving counts may be needed to reach efficacious doses. Sachet formats offer an alternative delivery form with better stability and higher payload per serving.

Pack-copy guidance should use only EFSA-authorised claim wording verbatim for EU markets. For example, "EPA and DHA contribute to the normal function of the heart" or "DHA contributes to the maintenance of normal brain function." Avoid "anti-inflammatory" in EU pack copy. For US markets, structure-function claims such as "Supports heart health" are permitted with the FDA disclaimer. DAT confirms claim eligibility, dosage, and certification status per project. No disease claims, no certification promises on pack until confirmed, and no guaranteed shelf-life until stability data is available.